Rev Med UAS
Vol. 13: No. 3. Julio-Septiembre 2023
ISSN 2007-8013

Beneficios terapéuticos de la oxigenoterapia hiperbárica en la nefropatía diabética: Evidencia clínica y perspectivas

Therapeutic benefits of hyperbaric oxygen therapy in diabetic nephropathy: Clinical evidence and perspectives

Mitzi N.E. Gomez-Solis1, Julio C. Ramírez-Nava2, Omar I. Salas-Nolasco3, Bianca S. Romero-Martínez4, Edgar Flores-Soto4,*.

  1. Escuela de Posgrado en Sanidad Naval, Universidad Naval, Secretaría de Marina de México, 04800 Veracruz, México.
  2. Centro médico naval, Especialista en Medicina Subacuática e Hiperbárica, 04470 CDMX, México.
  3. Hospital Naval de Especialidades de Veracruz, Especialista en Nefrología, 91700 Veracruz, México.
  4. Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 CDMX, México.

*Autor de correspondencia: Dr. Edgar Flores-Soto.
Universidad Nacional Autónoma de México.
Av. Universidad 3004, Copilco Universidad, Coyoacán. C. P. 04510 Ciudad de México, CDMX.
Tel (55)56232279. Correo electrónico: edgarfloressoto@yahoo.com.mx

DOI http://dx.doi.org/10.28960/revmeduas.2007-8013.v13.n3.006

Texto Completo PDF

Recibido 25 de agosto 2023, aceptado 23 de agosto 2023

RESUMEN
Objetivo: La nefropatía diabética (ND) representa una complicación grave de la diabetes mellitus (DM), caracterizada por la progresiva pérdida de la función renal. En los últimos años, la terapia de oxígeno hiperbárica (HBO2) ha emergido como una opción terapéutica innovadora para abordar esta compleja afección. Este artículo evalúa y analiza los efectos de la HBO2 sobre los marcadores claves de la ND, destacando sus implicaciones clínicas y perspectivas futuras. --- Material y Métodos: El estudio incluyó a pacientes en estadios 3 y 4 de ND y consistió en la administración de 20 sesiones de HBO2 a 2.3 ATA en una cámara hiperbárica. Se llevaron a cabo mediciones de hemoglobina glicosilada (HbA1c), tasa de filtración glomerular estimada (eFGR) y la relación albúmina/creatinina y se estratificaron los estadios clínicos antes y después del tratamiento con HBO2. --- Resultados: Antes de iniciar el tratamiento con HBO2, los pacientes presentaron valores iniciales de HbA1c, eFGR, creatinina y albuminuria sérica, y el índice de albuminuria/creatinina en orina de 8.12 ± 0.29 %, 38.68 ± 1.79 ml/min/1.73 m2, 1.85 ± 0.09 mg/dL, 131.47 ± 11.78 mg/l, y 78.74 ± 8.17 mg/g, respectivamente. Posteriormente al tratamiento, los valores fueron de 7.2 ± 0.25%, 53.16 ± 2.58 ml/min/ 1.73 m2, 1.47 ± 0.07 mg/dL, 117.56 ± 11.35 mg/l y 82.12 ± 8.52 mg/g, respectivamente. --- Conclusiones: La HBO2 emerge como una terapia adyuvante prometedora para la ND, con efectos positivos demostrados en marcadores clave y un potencial para mejorar la atención de los pacientes brindando esperanzas y enfoques en el tratamiento.
Palabras claves: Nefropatía diabética, hemoglobina glicosilada, tasa de filtrado glomerular, terapia de oxigenoterapia hiperbárica.

Summary
Objective: Diabetic nephropathy (DN) represents a serious complication of diabetes mellitus (DM), characterized by the progressive loss of kidney function. In recent years, hyperbaric oxygen therapy (HBO2) has emerged as an innovative therapeutic option to address this complex condition. This article evaluates and analyzes the effects of HBO2 on key markers of ND, highlighting its clinical implications and future perspectives. --- Material and Methods: The study included patients in stages 3 and 4 of ND and consisted of the administration of 20 sessions of HBO2 at 2.3 ATA in a hyperbaric chamber. Measurement of glycosylated hemoglobin (HbA1c) estimated, glomerular filtration rate (eGFR) and albumin/creatinine ratio were carried out and clinical stages were stratified before and after treatment with HBO2. --- Results: Before starting treatment with HBO2, patients presented initial values of HbA1c, eGFR, serum creatinine and albuminuria, and the urine albuminuria/creatinine index of 8.12 ± 0.29 %, 38.68 ± 1.79 ml/min/1.73 m2, 1.85 ± 0.09 mg/dL, 131.47 ± 11.78 mg/l, y 78.74 ± 8.17 mg/g, respectively. After treatment, the values were 7.2 ± 0.25%, 53.16 ± 2.58 ml/min/ 1.73 m2, 1.47 ± 0.07 mg/dL, 117.56 ± 11.35 mg/l y 82.12 ± 8.52 mg/g, respectively. --- Conclusions: HBO2 is emerging as a promising adjuvant therapy for ND, with demonstrated positive effects on key markers and the potential to improve patient care by providing new hope and approaches in treatment.
Key words: Diabetic nephropathy, glycosylated hemoglobin, glomerular filtration rate, hyperbaric oxygen therapy

Referencias

  1. Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018;71(6):884-95.
  2. International Diabetes Federation. IDF Diabetes Atlas Brussels 10th Ed. Belgium: 2021. [Available from]: https://www.diabetesatlas.org.
  3. Kanwar YS, Sun L, Xie P, Liu F-Y, Chen S. A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy. Annu Rev Pathol. 2011;6(1):395-423.
  4. De Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4):S1-S115.
  5. Harrison LE, Giardina C, Hightower LE, Anderson C, Perdrizet GA. Might hyperbaric oxygen therapy (HBOT) reduce renal injury in diabetic people with diabetes mellitus? From preclinical models to human metabolomics. Cell Stress and Chap. 2018;23(6):1143-52.
  6. Cárdenas-Ureña KG, Ramírez-Nava JC, Márquez-Celedonio FG, Salas-Nolasco OI, Villegas-Domínguez JE, Crespo-Cortés CN. Clinical efficacy of adjuvant therapy with hyperbaric oxygen in diabetic nephropathy. Undersea Hyperb Med. 2020;47(3):415–22.
  7. Thom SR. Hyperbaric Oxygen: Its Mechanisms and Efficacy. Plast Reconstr Surg. 2011;127:131S-41S.
  8. Jiang W, Wang J, Shen X, Lu W, Wang Y, Li W, et al. Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-Analysis of 20 Cohorts. Diabetes Cr. 2020;43(4):925–33.
  9. Irawan H, Semadi IN, Widiana IGR. A Pilot Study of Short-Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine in Patients with Diabetic Foot Ulcer Wagner 3-4. Sci Wrld J. 2018;2018:1-6.
  10. Estrada EJ, Decima JL, Bortman G, Roberti J, Romero EB, Samaja G, et al. Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial. Cell Transplant. 2019;28(12):1632-40.
  11. Nørlinger TS, Nielsen PM, Qi H, Mikkelsen E, Hansen K, Schmidt NH, et al. Hyperbaric oxygen therapy reduces renal lactate production. Physiol Rep. 2017;5(6):e13217.
  12. Gün RD, Gümüş T, Kardaş ASY, Kardaş G. Acute effect of hyperbaric oxygen therapy on macular and choroidal thickness in patients with type 2 diabetes and diabetic foot ulcers: Optical coherence tomography based study. Photodiagnosis Photodyn Ther. 2022;39:102926.
  13. Verma R, Chopra A, Giardina C, Sabbisetti V, Smyth JA, Hightower LE, et al. Hyperbaric oxygen therapy (HBOT) suppresses biomarkers of cell stress and kidney injury in diabetic mice. Cell Stress and Chap. 2015;20(3):495-505.
  14. Nesovic Ostojic J, Ivanov M, Mihailovic-Stanojevic N, Karanovic D, Kovacevic S, Brkic P, et al. Hyperbaric Oxygen Preconditioning Upregulates Heme OxyGenase-1 and Anti-Apoptotic Bcl-2 Protein Expression in Spontaneously Hypertensive Rats with Induced Postischemic Acute Kidney Injury. Int J Mol Sci. 2021;22(3):1382.
  15. Rubinstein I, Abassi Z, Milman F, Ovcharenko E, Coleman R, Winaver J, et al. Hyperbaric oxygen treatment improves GFR in rats with ischaemia/reperfusion renal injury: a possible role for the antioxidant/oxidant balance in the ischaemic kidney. Nephrol Dial Transplant. 2009;24(2): 428–36.
  16. Edremitlioğlu M, Kiliç D, Öter Ş, Kisa Ü, Korkmaz A, Coşkun Ö, et al. The Effect of Hyperbaric Oxygen Treatment on the Renal Functions in Septic Rats: Relation to Oxidative Damage. Surg Tdy. 2005;35(8):653-61.